{
  "docId": "019de075-dd1e-7468-9323-d12fde1b7732",
  "docSlug": "a9cc0c508d45d8985f57408ace49b969",
  "documentTitle": "RayzeBio | IPO Presentation Deck | 41 slides",
  "authorId": "rayzebio",
  "authorName": "RayzeBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 15,
  "pageCount": 41,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a chemical structure comparison to illustrate the similarity in binder/chelator while highlighting the difference in radioisotope.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/15",
  "deckHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732",
  "deckJsonHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json",
  "deckAnchorHref": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "image",
      "text": "Chemical structures of Lutathera and RYZ101",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5189ce30-a936-498d-95f3-fffb5cbf5206",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.51,
        "y": 0.32
      },
      "kind": "list",
      "text": "Evaluate RYZ101 in GEP-NET patients previously treated with 177Lu SSA that have progressed; Use similar dosing schedule frequency; Use clinical trial sites that have experience with Lutathera; IP estate on novel RYZ101 extends to 2042",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fb9e79a-7c6e-4470-a0c9-b85065a7a6cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "list",
      "text": "Lutathera and RYZ101 share the same binder and chelator – DOTATATE; RYZ101 has more potent alpha radioisotope 225Ac; Novel proprietary formulation developed on RYZ101",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdff5faf-eed3-4f34-b629-84e02bd981a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.51,
        "y": 0.27
      },
      "kind": "paragraph",
      "text": "Development strategy",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7de78c86-eb01-4a74-94f5-200a7ae8af46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "RYZ101 (225Ac-DOTATATE) – Addresses the Unmet Need in NETs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40f6aa0a-9305-4a5f-911b-aa0a50277352",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}